Archive: October, 2012
Former U.S. Food and Drug Administration Commissioner David Kessler, a pediatrician by training, said that Johnson & Johnson and its Janssen subsidiary broke the law in marketing its antipsychotic drug Risperdal for use in children and adolescents.
"In my opinion," Kessler wrote in a report submitted for a trial set to begin Oct. 9 in in Philadelphia's Court of Common Pleas, "Janssen promoted Risperdal for non-approved uses in violation of the Federal Food, Drug, and Cosmetic Act."
(UPDATE: J&J settled four so-called bellweather cases Thursday morning for undisclosed amounts. Asked if the prospect of Kessler testifying against the company prompted it to offer enough to settle, plaintiffs' attorney Stephen Sheller said, "Yes.")
The Atlantic magazine, with drugmaker GlaxoSmithKline as a sponsor, last week launched the first of several panel discussions that it is calling "A Conversation on Community Health."
The first panel and town hall meeting was held at WHYY in Philadelphia.
Philadelphia's Bill Cosby was the most famous panelist, but The Atlantic's Vice President Elizabeth Baker Keffer and GSK's North America Pharmaceuticals President Deirdre Connelly welcomed panelists and the audience.